Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

Guide on how to set-up Linux and Docker for real-time applications using the Ubuntu realtime-kernel/PREEMPT_RT patch with a focus on robotics with ROS and ROS 2 ...

In other dev-related news Tuesday, OpenAI announced new versions of its GPT-4o and GPT-4o mini models as part of the Realtime API, OpenAI’s API for building apps with low-latency, AI-generated ...

Vertex Pharmaceuticals (VRTX ... on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges ...

Ligand Pharmaceuticals Inc. continues to attract positive attention from analysts, with price targets ranging from $110 to $150. The company's unique business model, recent product approvals, and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The revenue for Inaxaplin is expected to reach an annual total of $138 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue ... It acts by targeting APO-L1 function. Vertex ...